In survey data presented at EADV 2026, 39% of GLP-1 users reported nails lifting versus 9% of nonusers. The lead author says overall health likely explains much of the gap.
Recap by typeshit. Full story at Healthline.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
She walks through how Lilly tested the combination in 367 adults with obesity or overweight, a trial she says reached 23% weight loss.
In Malayalam, the endocrinologist argues that treating the drugs as a quick fix raises the chance of side effects, and that better health should be the main goal.
Loading…